Published in Mov Disord on January 01, 2008
Sham surgery trial controls: perspectives of patients and their relatives. J Empir Res Hum Res Ethics (2012) 0.87
Randomised placebo-controlled trials of surgery: ethical analysis and guidelines. J Med Ethics (2016) 0.82
Challenges in the evaluation, consent, ethics and history of early clinical trials - Implications of the Tuskegee 'trial' for safer and more ethical clinical trials. Curr Opin Mol Ther (2009) 0.81
Attitudes and beliefs about placebo surgery among orthopedic shoulder surgeons in the United Kingdom. PLoS One (2014) 0.80
Strengthening the ethical assessment of placebo-controlled surgical trials: three proposals. BMC Med Ethics (2014) 0.79
Potential cellular and regenerative approaches for the treatment of Parkinson's disease. Neuropsychiatr Dis Treat (2008) 0.79
What every urologist should know about surgical trials Part I: Are the results valid? Indian J Urol (2008) 0.78
Placebo in Surgical Research: A Case-Based Ethical Analysis and Practical Consequences. Biomed Res Int (2016) 0.76
Advance directives and outcomes of surrogate decision making before death. N Engl J Med (2010) 7.09
Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. N Engl J Med (2014) 6.67
Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med (2007) 6.09
Levodopa and the progression of Parkinson's disease. N Engl J Med (2004) 5.44
Early surgical therapy for drug-resistant temporal lobe epilepsy: a randomized trial. JAMA (2012) 5.40
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord (2004) 4.83
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol (2002) 4.60
HIV-associated cognitive impairment before and after the advent of combination therapy. J Neurovirol (2002) 4.20
A phase 3 trial of semagacestat for treatment of Alzheimer's disease. N Engl J Med (2013) 4.11
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 3.84
Association between stroke center hospitalization for acute ischemic stroke and mortality. JAMA (2011) 3.68
Preparing for preventive clinical trials: the Predict-HD study. Arch Neurol (2006) 3.57
Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med (2008) 3.54
The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. Blood (2005) 3.22
Informed consent for pragmatic trials--the integrated consent model. N Engl J Med (2014) 3.01
Long QT syndrome in adults. J Am Coll Cardiol (2007) 2.93
Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol (2003) 2.81
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Proactive palliative care in the medical intensive care unit: effects on length of stay for selected high-risk patients. Crit Care Med (2007) 2.76
A review of the evidence for the use of telemedicine within stroke systems of care: a scientific statement from the American Heart Association/American Stroke Association. Stroke (2009) 2.74
Financial anatomy of neuroscience research. Ann Neurol (2006) 2.71
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation (2008) 2.40
Systematic review: Hydroxyurea for the treatment of adults with sickle cell disease. Ann Intern Med (2008) 2.31
Bacterial complications of respiratory tract viral illness: a comprehensive evaluation. J Infect Dis (2013) 2.29
What is the risk of sham surgery in Parkinson disease clinical trials? A review of published reports. Neurology (2005) 2.25
Modulating effects of age and gender on the clinical course of long QT syndrome by genotype. J Am Coll Cardiol (2003) 2.22
Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-go-related gene potassium channel. Circulation (2002) 2.20
Beyond disgust: impaired recognition of negative emotions prior to diagnosis in Huntington's disease. Brain (2007) 2.17
Risk of aborted cardiac arrest or sudden cardiac death during adolescence in the long-QT syndrome. JAMA (2006) 2.12
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol (2004) 2.02
A randomized, placebo-controlled trial of oxycodone and of gabapentin for acute pain in herpes zoster. Pain (2009) 2.01
TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2006) 1.95
An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol (2007) 1.94
Mutations in cytoplasmic loops of the KCNQ1 channel and the risk of life-threatening events: implications for mutation-specific response to β-blocker therapy in type 1 long-QT syndrome. Circulation (2012) 1.89
Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol (2013) 1.83
Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretroviral therapy. Arch Neurol (2004) 1.79
Science and ethics of sham surgery: a survey of Parkinson disease clinical researchers. Arch Neurol (2005) 1.77
Long-QT syndrome after age 40. Circulation (2008) 1.73
A systematic review of barriers and interventions to improve appropriate use of therapies for sickle cell disease. J Natl Med Assoc (2009) 1.70
Neoadjuvant gemcitabine and cisplatin chemotherapy for locally advanced urothelial cancer of the bladder. Cancer (2011) 1.62
Risk factors for recurrent syncope and subsequent fatal or near-fatal events in children and adolescents with long QT syndrome. J Am Coll Cardiol (2011) 1.59
Financing of U.S. biomedical research and new drug approvals across therapeutic areas. PLoS One (2009) 1.55
Verbal episodic memory declines prior to diagnosis in Huntington's disease. Neuropsychologia (2007) 1.54
Sham neurosurgical procedures in clinical trials for neurodegenerative diseases: scientific and ethical considerations. Lancet Neurol (2012) 1.54
Human metapneumovirus infections in adults: another piece of the puzzle. Arch Intern Med (2008) 1.53
Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn (2006) 1.53
Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord (2006) 1.53
Health state preferences and decision-making after malignant middle cerebral artery infarctions. Neurology (2010) 1.52
A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol (2005) 1.48
Corrected QT variability in serial electrocardiograms in long QT syndrome: the importance of the maximum corrected QT for risk stratification. J Am Coll Cardiol (2006) 1.48
Test-retest reliability of the unified Parkinson's disease rating scale in patients with early Parkinson's disease: results from a multicenter clinical trial. Mov Disord (2002) 1.48
Why have we failed to achieve neuroprotection in Parkinson's disease? Ann Neurol (2008) 1.47
Toward more efficient clinical trials for amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2010) 1.45
Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Mov Disord (2013) 1.41
The idiopathic intracranial hypertension treatment trial: design considerations and methods. J Neuroophthalmol (2014) 1.40
Systematic review of community-based childhood obesity prevention studies. Pediatrics (2013) 1.36
An approach to evaluating the therapeutic misconception. IRB (2009) 1.35
Pivotal studies of orphan drugs approved for neurological diseases. Ann Neurol (2009) 1.34
Risk factors for severe respiratory syncytial virus infection in elderly persons. J Infect Dis (2004) 1.34
Disclosing individual CDKN2A research results to melanoma survivors: interest, impact, and demands on researchers. Cancer Epidemiol Biomarkers Prev (2011) 1.32
Defining "success" in recruitment of underrepresented populations to cancer clinical trials: moving toward a more consistent approach. Cancer (2006) 1.30
Assessment of decision-making capacity: views and experiences of consultation psychiatrists. Psychosomatics (2012) 1.29
Evidence, preferences, recommendations--finding the right balance in patient care. N Engl J Med (2012) 1.26
Returning individual research results: development of a cancer genetics education and risk communication protocol. J Empir Res Hum Res Ethics (2010) 1.22
Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol (2002) 1.22
Pragmatic Randomized Trials Without Standard Informed Consent?: A National Survey. Ann Intern Med (2015) 1.20
The views of Alzheimer disease patients and their study partners on proxy consent for clinical trial enrollment. Am J Geriatr Psychiatry (2008) 1.19
Palliative and end-of-life care in stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke (2014) 1.17
Adverse prognostic factors for testicular cancer-specific survival: a population-based study of 27,948 patients. J Clin Oncol (2011) 1.15
Interrater agreement in the assessment of motor manifestations of Huntington's disease. Mov Disord (2005) 1.13
The relationship between CAG repeat length and clinical progression in Huntington's disease. Mov Disord (2008) 1.12
Interpreting the clinical significance of capacity scores for informed consent in Alzheimer disease clinical trials. Am J Geriatr Psychiatry (2008) 1.10
Utility of serum procalcitonin values in patients with acute exacerbations of chronic obstructive pulmonary disease: a cautionary note. Int J Chron Obstruct Pulmon Dis (2012) 1.08
The evolving role and value of libraries and librarians in health care. JAMA (2013) 1.07
Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer. Thromb Haemost (2011) 1.07
Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible? J Infect Dis (2007) 1.07
Early stroke mortality, patient preferences, and the withdrawal of care bias. Neurology (2012) 1.07
Phase II study of a TLR-9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. Br J Haematol (2009) 1.07
The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation. Med Decis Making (2007) 1.03
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials. Clin Trials (2005) 1.02
Is psychiatric research stigmatized? An experimental survey of the public. Schizophr Bull (2005) 1.02
Lithium therapy for human immunodeficiency virus type 1-associated neurocognitive impairment. J Neurovirol (2009) 1.02
Symptomatic and palliative care for stroke survivors. J Gen Intern Med (2012) 1.02
Impact of pramipexole on the onset of levodopa-related dyskinesias. Mov Disord (2007) 1.01
Development and testing of the Parkinson's disease quality of life scale. Mov Disord (2003) 1.01
Risk factors for respiratory failure associated with respiratory syncytial virus infection in adults. J Infect Dis (2009) 1.00
Research participants' "irrational" expectations: common or commonly mismeasured? IRB (2013) 1.00
What's it worth? Public willingness to pay to avoid mental illnesses compared with general medical illnesses. Psychiatr Serv (2012) 1.00
Treatment decisions after severe stroke: uncertainty and biases. Stroke (2012) 1.00
Impact of long-term serum platinum concentrations on neuro- and ototoxicity in Cisplatin-treated survivors of testicular cancer. J Clin Oncol (2011) 0.99
Malignant melanoma in early Parkinson's disease: the DATATOP trial. Mov Disord (2007) 0.99